Novel Small-Molecule Drug Candidate for Oncology

OCR Number: OCR 1642

Description:

- GFB-204 is a novel compound that binds PDGF and VEGF and prevents binding to their respective receptors, and subsequently suppresses downstream signaling pathways.
- GFB-204 is selective for PDGF and VEGF, and does not inhibit EGF, IGF-1 and FGF stimulation of Erk1/2, Akt, and STAT3.
- As shown in the figure, GFB-204 causes a marked decrease in tumor volume in a mouse xenograft model.
- Inhibition of VEGF and PDGF receptor binding with GFB-204 results in potent inhibition of angiogenesis and tumorigenesis.
- IND-enabling studies have been initiated for GFB-204 for AMD and cancer.

Published/Issued Patents: [U.S. Patent No. 7,482,483](https://www.google.com)

Published/Issued Patents: [U.S. Patent No. 7,718,700](https://www.google.com)

Published/Issued Patents: [PCT App. Pub. No. WO2005072779](https://www.google.com)

Publications:

Licensing Contact: John Puziss
john.puziss@yale.edu